Market Currents
Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung...
-
Monday, July 25, 2011, 12:20 PM ETOncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung cancer drug Stimuvax. He asserts the drug is poorly designed, fails to improve lung cancer survival and is not likely to pass its phase III testing trials.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 5 comments:
red